INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

BVSBioventus Inc.

CIK 0001665988

EDGAR filingsOpen in network
Disclosed transactions24
Buys / sells0 / 2
Max Insider Score32
Connections5with evidence

BVS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
MM
McMurry-Heath MichelleDirector
BVSBioventus Inc.
Option exercise
M—
32.3K sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 3841 · Surgical & Medical Instruments & Apparatus · Nov 4, 2026
  • ← Insider ofevidence
    D'Adamio AnthonySVP & General Counsel · Apr 14, 2026
  • ← Insider ofevidence
    Singleton Mark LeonardSVP & CFO · Mar 24, 2026
  • ← Insider ofevidence
    Claypoole Robert EDirector, President and CEO · Jan 13, 2026
5
MM
McMurry-Heath MichelleDirector
BVSBioventus Inc.
Grant or award
A
—
25.1K sh
Jun 3, 2026
Jun 4, 2026
traded Jun 3, 2026
+1d
SEC FORM 4

Evidence

17
MM
McMurry-Heath MichelleDirector
BVSBioventus Inc.
Option exercise
M—
32.3K sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

9
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Option exercise
M—
13.0K sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

12
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Tax withholding
F$51K
5,648 sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

13
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Option exercise
M—
13.0K sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

13
DA
D'Adamio AnthonySVP & General Counsel
BVSBioventus Inc.
Option exercise
M—
9,925 sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

9
DA
D'Adamio AnthonySVP & General Counsel
BVSBioventus Inc.
Tax withholding
F$39K
4,312 sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

9
DA
D'Adamio AnthonySVP & General Counsel
BVSBioventus Inc.
Option exercise
M—
9,925 sh
Apr 10, 2026Apr 14, 2026
traded Apr 10, 2026
+4dSEC FORM 4

Evidence

9
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Option exercise
M—
18.6K sh
Mar 20, 2026Mar 24, 2026
traded Mar 20, 2026
+4dSEC FORM 4

Evidence

12
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Tax withholding
F$70K
8,091 sh
Mar 20, 2026Mar 24, 2026
traded Mar 20, 2026
+4dSEC FORM 4

Evidence

13
SL
Singleton Mark LeonardSVP & CFO
BVSBioventus Inc.
Option exercise
M—
18.6K sh
Mar 20, 2026Mar 24, 2026
traded Mar 20, 2026
+4dSEC FORM 4

Evidence

16
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Tax withholding
F$125K
14.6K sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

17
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
33.5K sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

24
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Grant or award
A—
134.0K sh
Mar 14, 2025Mar 17, 2026
traded Mar 14, 2025
+368dSEC FORM 4

Evidence

24
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Grant or award
A—
153.0K sh
Mar 14, 2025Mar 17, 2026
traded Mar 14, 2025
+368dSEC FORM 4

Evidence

9
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Grant or award
A—
278.0K sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

9
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Grant or award
A—
309.0K sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

21
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
33.5K sh
Mar 13, 2026Mar 17, 2026
traded Mar 13, 2026
+4dSEC FORM 4

Evidence

28
MM
McMurry-Heath MichelleDirector
BVSBioventus Inc.
Open-market sale
SELL$105K
12.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

21
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
93.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

27
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Tax withholding
F$335K
41.7K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

21
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
93.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

32
MM
McMurry-Heath MichelleDirector
BVSBioventus Inc.
Open-market sale
SELL$131K
17.7K sh
Nov 7, 2025Nov 10, 2025
traded Nov 7, 2025
+3dSEC FORM 4

Evidence

  • ← Insider ofevidence
    McMurry-Heath MichelleDirector · Nov 10, 2025